SMT202200087T1 - Amminoimidazopiridazine come inibitori di chinasi - Google Patents

Amminoimidazopiridazine come inibitori di chinasi

Info

Publication number
SMT202200087T1
SMT202200087T1 SM20220087T SMT202200087T SMT202200087T1 SM T202200087 T1 SMT202200087 T1 SM T202200087T1 SM 20220087 T SM20220087 T SM 20220087T SM T202200087 T SMT202200087 T SM T202200087T SM T202200087 T1 SMT202200087 T1 SM T202200087T1
Authority
SM
San Marino
Prior art keywords
aminoimidazopyridazines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
SM20220087T
Other languages
English (en)
Italian (it)
Inventor
Jason M Guernon
John E Macor
Jianliang Shi
Amy C Hart
Guanglin Luo
Carolyn Diane Dzierba
Steven H Spergel
Michael E Mertzman
William J Pitts
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT202200087T1 publication Critical patent/SMT202200087T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20220087T 2017-10-30 2018-10-29 Amminoimidazopiridazine come inibitori di chinasi SMT202200087T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762578607P 2017-10-30 2017-10-30
US201862626853P 2018-02-06 2018-02-06
EP18804177.6A EP3704118B1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridazines as kinase inhibitors
PCT/US2018/057968 WO2019089442A1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
SMT202200087T1 true SMT202200087T1 (it) 2022-03-21

Family

ID=64332173

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220087T SMT202200087T1 (it) 2017-10-30 2018-10-29 Amminoimidazopiridazine come inibitori di chinasi

Country Status (23)

Country Link
US (1) US11440913B2 (enExample)
EP (1) EP3704118B1 (enExample)
JP (1) JP7228586B2 (enExample)
KR (1) KR102662197B1 (enExample)
CN (1) CN111566103B (enExample)
AU (1) AU2018361249B2 (enExample)
BR (1) BR112020007557A2 (enExample)
CA (1) CA3080402A1 (enExample)
CY (1) CY1124984T1 (enExample)
DK (1) DK3704118T3 (enExample)
ES (1) ES2905948T3 (enExample)
HR (1) HRP20220297T1 (enExample)
HU (1) HUE058292T2 (enExample)
IL (1) IL274207B2 (enExample)
LT (1) LT3704118T (enExample)
MX (1) MX2020003706A (enExample)
PL (1) PL3704118T3 (enExample)
PT (1) PT3704118T (enExample)
RS (1) RS62974B1 (enExample)
SG (1) SG11202003824PA (enExample)
SI (1) SI3704118T1 (enExample)
SM (1) SMT202200087T1 (enExample)
WO (1) WO2019089442A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148626A1 (en) 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
JP7599411B2 (ja) 2018-09-13 2024-12-13 ブリストル-マイヤーズ スクイブ カンパニー 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
KR20220079593A (ko) * 2019-10-03 2022-06-13 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
WO2021168521A1 (en) * 2020-02-27 2021-09-02 Anaxis Pharma Pty Ltd Inhibitors of necroptosis
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
JP2023544892A (ja) * 2020-10-13 2023-10-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 置換4-([1,2,4]トリアゾロ[1,5-a]ピリジン-6-イル)チオフェン-2-カルボキサミド誘導体及びその使用
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN120530112A (zh) * 2022-12-30 2025-08-22 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
JP5589003B2 (ja) * 2009-02-04 2014-09-10 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 脂質障害のような代謝疾患の処置のために有用な[1,3]オキサジン−2−オンの誘導体
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CA2914668A1 (en) 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
BR112018072552A8 (pt) 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018148626A1 (en) 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
JP7599411B2 (ja) 2018-09-13 2024-12-13 ブリストル-マイヤーズ スクイブ カンパニー 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド
WO2020097400A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof

Also Published As

Publication number Publication date
BR112020007557A2 (pt) 2020-09-24
WO2019089442A1 (en) 2019-05-09
EP3704118A1 (en) 2020-09-09
SG11202003824PA (en) 2020-05-28
KR102662197B1 (ko) 2024-04-29
DK3704118T3 (da) 2022-03-14
AU2018361249B2 (en) 2022-08-25
JP2021501179A (ja) 2021-01-14
PL3704118T3 (pl) 2022-04-04
ES2905948T3 (es) 2022-04-12
IL274207A (en) 2020-06-30
IL274207B2 (en) 2023-04-01
CY1124984T1 (el) 2023-01-05
CA3080402A1 (en) 2019-05-09
CN111566103A (zh) 2020-08-21
US20200277296A1 (en) 2020-09-03
WO2019089442A8 (en) 2019-06-27
SI3704118T1 (sl) 2022-04-29
HUE058292T2 (hu) 2022-07-28
US11440913B2 (en) 2022-09-13
AU2018361249A1 (en) 2020-06-11
PT3704118T (pt) 2022-02-14
KR20200078591A (ko) 2020-07-01
JP7228586B2 (ja) 2023-02-24
EP3704118B1 (en) 2022-01-12
IL274207B (en) 2022-12-01
HRP20220297T1 (hr) 2022-05-13
CN111566103B (zh) 2023-06-23
MX2020003706A (es) 2020-07-22
LT3704118T (lt) 2022-02-25
RS62974B1 (sr) 2022-03-31

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
IL279258B (en) tyrosine kinase inhibitors
IL275207A (en) An oxyfluoropiperidine derivative as a kinase inhibitor
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
SG11202004918XA (en) Amino-fluoropiperidine derivative as kinase inhibitor
IL269063B (en) Pyrimidopyrimidinones used as wee-1 kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors
AU2015904223A0 (en) Novel kinase inhibitors i
AU2015903106A0 (en) Novel kinase inhibitors ii